头孢他啶/阿维巴坦在重症革兰氏阴性菌感染临床治疗中的研究进展  

Research progress on ceftazidime/avibactam in the clinical treatment of severe Gram-negative bacteria infection

作　　者：赵宗彪 赵为陈 何春远 蒋俊杰 沈炳香 王法财 ZHAO Zongbiao;ZHAO Weichen;HE Chunyuan;JIANG Junjie;SHEN Bingxiang;WANG Facai(Department of Pharmacy,Lu'an Hospital of Anhui Medical University(Lu'an People's Hospital),Lu'an 237005,Anhui Province,China)

机构地区：[1]安徽医科大学附属六安医院(六安市人民医院)药学部,安徽六安237005

出　　处：《世界临床药物》2024年第3期327-332,共6页World Clinical Drug

基　　金：六安市科学技术局基金项目(2023lakj002);六安市人民医院院级课题项目(2023kykt02);安徽医科大学校科研基金项目(2023xkj078)。

摘　　要：头孢他啶(ceftazidime)/阿维巴坦(avibactam)是第3代头孢他啶与新型非β-内酰胺酶抑制剂组合的复合制剂。目前已获批用于治疗医院获得性肺炎(pneumonia)、呼吸机相关性肺炎及复杂性腹腔感染等治疗药物有限的重症感染,且逐步在复杂性尿路感染、颅内感染的临床治疗中开展应用,并表现出明显优势。该文主要从头孢他啶/阿维巴坦的药理作用、药代动力学、临床应用及用药方法等方面作综述,以期为临床用药提供一定参考,促进合理用药。Ceftazidime/avibactam is a combination of third-generation ceftazidime and novel non-beta-lactamase inhibitors.At present,it has been approved for the clinical treatment of severe infections with limited therapeutic drugs such as hospital-acquired pneumonia,ventilator-associated pneumonia,and complex abdominal infection,and it also has been gradually applied in the clinical treatment of complex urinary tract infection and intracranial infection,and has shown obvious advantages.This article summarized the pharmacological action,pharmacokinetics,clinical application and drug use methods of ceftazidime/avibactam,in order to provide some reference for clinical drug selection and promote rational drug use.

关 键 词：头孢他啶/阿维巴坦 革兰氏阴性菌 感染 临床治疗 

分 类 号：R978.1[医药卫生—药品] R515[医药卫生—药学]